论文部分内容阅读
根据大量临床试验结果对治疗急性心肌梗死(AMI)的溶栓药物从疗效、并发症等进行了比较,发现溶栓药物从第1代到第3代在纤维蛋白选择性、半衰期、给药方式等方面有了较大的改进,使AMI的病死率降至7%~8%,但新型溶栓药物在有效率方面并没有明显超过组织型纤溶酶原激活剂,仍存在着颅内出血并发症、价格昂贵等缺点。因此,积极联用抗栓药物和经皮冠状动脉介入术治疗AMI,乃是降低病死率的倡用办法。
According to the results of a large number of clinical trials for the treatment of acute myocardial infarction (AMI) thrombolytic drugs from the efficacy, complications were compared and found thrombolytic drugs from the first generation to the third generation in the fibrin selectivity, half-life, And other aspects have been greatly improved, the mortality rate of AMI dropped to 7% to 8%, but the new type of thrombolytic drugs did not significantly exceed the efficiency of tissue-type plasminogen activator, there are still complicated by intracranial hemorrhage Symptoms, expensive and other shortcomings. Therefore, the active combination of antithrombotic drugs and percutaneous coronary intervention for the treatment of AMI, is to reduce the mortality of the advocacy approach.